Detalhe da pesquisa
1.
LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity.
Nature
; 611(7934): 148-154, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171287
2.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
Breast Cancer Res
; 25(1): 2, 2023 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36631725
3.
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
Mol Cancer Ther
; 23(1): 84-91, 2024 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774393
4.
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Nat Commun
; 15(1): 466, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38212321
5.
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Clin Cancer Res
; 29(8): 1569-1581, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36730339
6.
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
Cancer Cell
; 2(2): 127-37, 2002 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12204533